All results

9 results for phase 2 randomized double blind placebo controlled parallel arm study evaluate

• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

  This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…

  Ages

  18 Years - N/A

  Sexes

  All

• Edgewise-210

  The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…

  Ages

  4 Years - 9 Years

  Sexes

  Male

• CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

  This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK),…

  Ages

  40 Years - N/A

  Sexes

  All

• IMPALA-2

  160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…

  Ages

  18 Years - N/A

  Sexes

  All

• GCAptAIN

  This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…

  Ages

  50 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• Armata

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• ALXN2050-NEPH-201

  This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All